Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune (ALT – Research Report) on February 28 and set a price target of $25.00.

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

Altimmune (NASDAQ:ALT) Inc. reported its fourth-quarter 2024 earnings, revealing a slight beat on EPS forecasts with an actual EPS of -0.33 compared to the forecasted -0.34. Revenue, however, was ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full ...